Abstract:BackgroundLiquid biopsy has been proposed to be a promising noninvasive tool to obtain information on tumor progression. Through a clinical observation of a case series of 6 consecutive patients, we aim to determine the value of circulating tumor DNA (ctDNA) for monitoring the tumor burden during the treatment of colorectal cancer (CRC).Materials and MethodsWe used capture sequencing of 545 genes to identify somatic alternations in primary tumor tissues of the six CRC patients who underwent radical surgery and in 23 plasma samples collected at serial time points. We compared the mutation patterns and variant allele frequencies (VAFs) between the matched tissue and the plasma samples and evaluated the potential advantage of using ctDNA as a better tumor load indicator to detect disease relapse over carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9 and imaging studies.ResultsWe identified low-frequency mutations with a mean VAF of 0.88% (corresponding to a mean tumor burden of 0.20ng/mL) in the preoperative plasmas of four patients with locally advanced CRC and a subset of mutations shared by their primary tumors. The tumor loads appeared a sudden decrease upon surgery or other adjuvant treatments and then generally maintained at low levels (0.092ng/mL) until disease recurred. ctDNA increased by 13-fold when disease relapsed in one patient while the CEA and CA 19-9 levels remained normal. In this patient, all six somatic mutations identified in the preoperative plasma were detected in the recrudescent plasma again, with five mutations showing allele fraction increase.ConclusionsWe described a multi-time-point profile of ctDNA of CRC patients during the course of comprehensive treatment and observed a correlation of ctDNA level with the clinically evaluated tumor progression. This demonstrated a new strategy by analyzing the heterogeneous ctDNA to evaluate and monitor the tumor burden in the treatment and follow-up of CRC patients, with potentially better potency than conventional biomarkers.

Circulating Dna As Potential Biomarker for Cancer Individualized Therapy

Circulating tumor DNA analysis for tumor diagnosis

Clinical Applications Of Circulating Tumor Dna In Monitoring Breast Cancer Drug Resistance

Circulating tumor DNA: from discovery to clinical application in breast cancer

The feasibility of using mutation detection in ctDNA to assess tumor dynamics

Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques

Non-blood Circulating Tumor DNA Detection in Cancer

Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer

Application of Circulating Tumor DNA As a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer

Circulating Tumor Cells and Individualized Chemotherapy

Nanotechnology Strategies For The Analysis Of Circulating Tumor Dna: A Review

Circulating tumor DNA methylation: a promising clinical tool for cancer diagnosis and management

Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer

Role of circulating-tumor DNA analysis in non-small cell lung cancer

Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening

Technical progress in circulating tumor DNA analysis using next generation sequencing

Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types

Application of Circulating Tumor DNA As a Biomarker for Non-Small Cell Lung Cancer

Application of Circulating Tumor DNA in Precision Diagnosis and Treatment of Colorectal Cancer

Cell-free Circulating Tumor DNA in Cancer